NVO vs VTVT
NVO: A leading global healthcare company with a heritage in diabetes, pioneering scientific breakthroughs to defeat serious chronic diseases through innovative medicines and expanded access. VTVT: A late-stage biopharmaceutical company developing cadisegliatin, a liver-selective glucokinase activator in Phase 3 trials for type 1 diabetes, with FDA Breakthrough Therapy designation.
Side-by-side fundamentals
| Metric | NVO | VTVT | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $48.19 | $31.67 | |
| Market cap as of 2026-07-23 | $219.8B | $124M | |
| P/E as of 2026-07-23 | 11.78 | 55.08 | NVO lower |
| PEG as of 2026-07-23 | 16.16 | n/a | |
| Net margin as of 2026-07-23 | +37.2% | +65.5% | VTVT higher |
| Gross margin as of 2026-07-23 | +81.8% | n/a | |
| Operating margin as of 2026-07-23 | +45.3% | +63.1% | VTVT higher |
| ROE as of 2026-07-23 | +66.4% | +4.0% | NVO higher |
| ROA as of 2026-07-23 | +23.3% | +2.9% | NVO higher |
| Debt / equity as of 2026-07-23 | 0.72 | 0.00 | VTVT lower |
| Revenue growth (YoY) as of 2026-07-23 | +8.1% | +216600.0% | VTVT higher |
| Dividend yield as of 2026-07-23 | +3.7% | n/a | |
| Beta as of 2026-07-23 | 1.85 | 0.29 | |
| 1-year return as of 2026-07-22 close | -23.8% | -69.6% | NVO higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.